Hydroxamic acid derivatives: a promising scaffold for rational compound optimization in Chagas disease

References

• Rassi A, Marcondes RJ. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 2012;26:275–91
   PubMed Web of Science ®Google Scholar
• WHO. Chagas disease-factsheet. Wkly Epidemiol Rec 2012;87:519–22
   PubMedGoogle Scholar
• Bocchi EA. Heart failure in South America. Curr Cardiol Rev 2013;9:147–56
   PubMedGoogle Scholar
• Strasen J, Williams T, Ertl G, et al. Epidemiology of chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol 2014;103:1–10
   PubMed Web of Science ®Google Scholar
• Jackson Y, Herrera V, Gascon J. Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe. Bull World Health Organ 2014;92:771–2
   PubMed Web of Science ®Google Scholar
• Carlier Y. Globalization of Chagas disease (American trypanosomiasis): the situation in Europe and Belgium. Bull Mem Acad R Med Belg 2011;166:347–55
   PubMedGoogle Scholar
• Sánchez LV, Ramírez JD. Congenital and oral transmission of American trypanosomiasis: an overview of physiopathogenic aspects. Parasitology 2012;140:1–13
   PubMed Web of Science ®Google Scholar
• Montgomery SP, Starr MC, Cantey PT, et al. Neglected parasitic infections in the United States: Chagas disease. Am J Trop Med Hyg 2014;90:814–18
   PubMed Web of Science ®Google Scholar
• Mejía-Jaramillo AM, Fernández G, Montilla M, et al. Trypanosoma cruzi strains resistant to benznidazole occurring in Colombia. Biomedica 2012;32:196–205
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Guerrero L, Posada E, et al. Benznidazole-related adverse drug reactions and their relationship with serum drug concentrations in patients with chronic Chagas disease. Antimicrob Agents Chemother 2012;57:390–5
   PubMed Web of Science ®Google Scholar
• Perez CJ, Lymbery AJ, Thompson RCA. Chagas disease: the challenge of polyparasitism? Trends Parasitol 2014;30:176–82
   PubMed Web of Science ®Google Scholar
• Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med 2014;370:1899–908
   PubMed Web of Science ®Google Scholar
• De Carvalho KAT, Abdelwahid E, Ferreira RJ, et al. Preclinical stem cell therapy in Chagas disease: perspectives for future research. World J Transplant 2013;3:119–26
   PubMedGoogle Scholar
• Bahia MT, Diniz L de F, Mosqueira VCF. Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opin Investig Drugs 2014;23:1225–37
   PubMed Web of Science ®Google Scholar
• Cencig S, Coltel N, Truyens C, Carlier Y. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents 2012;40:527–32
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Bottazzi ME, Zhan B, et al. Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Rev Vaccines 2012;11:1043–55
   PubMed Web of Science ®Google Scholar
• Ndao M, Beaulieu C, Black WC, et al. Reversible cysteine protease inhibitors show promise for a Chagas disease cure. Antimicrob Agents Chemother 2014;58:1167–78
   PubMed Web of Science ®Google Scholar
• Branquinha MH, Marinho FA, Sangenito LS, et al. Calpains: potential targets for alternative chemotherapeutic intervention against human pathogenic trypanosomatids. Curr Med Chem 2013;20:3174–85
   PubMed Web of Science ®Google Scholar
• Laverrière M, Cazzulo JJ, Alvarez VE. Antagonic activities of Trypanosoma cruzi metacaspases affect the balance between cell proliferation, death and differentiation. Cell Death Differ 2012;19:1358–69
   PubMed Web of Science ®Google Scholar
• Cazzulo JJ. Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease. Curr Top Med Chem 2002;2:1261–71
   PubMedGoogle Scholar
• Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005;49:5160–2
   PubMed Web of Science ®Google Scholar
• McKerrow JH, Doyle PS, Engel JC, et al. Two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 2009;104:263–9
   PubMed Web of Science ®Google Scholar
• Santos LO, Garcia-Gomes AS, Catanho M, et al. Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy. Curr Med Chem 2013;20:3116–33
   PubMed Web of Science ®Google Scholar
• Nogueira de Melo AC, de Souza EP, Elias CGR, et al. Detection of matrix metallopeptidase-9-like proteins in Trypanosoma cruzi. Exp Parasitol 2010;125:256–63
   PubMed Web of Science ®Google Scholar
• Nogueira de Melo AC, Meirelles MNSL, Porrozzi R, et al. Reduced activity of matrix metalloproteinase-9 in Trypanosoma cruzi-infected mouse embryo hepatocyte cell. Hepatol Res 2004;28:49–56
   PubMed Web of Science ®Google Scholar
• Rodrigues GC, Feijó DF, Bozza MT, et al. Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. J Med Chem 2014;57:298–308
   PubMed Web of Science ®Google Scholar
• McKenna R, Supuran CT. Carbonic anhydrase inhibitors drug design. Subcell Biochem 2014;75:291–323
   PubMedGoogle Scholar
• Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem 2013;56:1761–71
   PubMed Web of Science ®Google Scholar
• Meirelles MNSL, de Araújo-Jorge TC, Miranda CF, et al. Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. Eur J Cell Biol 1986;41:198–206
   PubMed Web of Science ®Google Scholar
• Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196–202
   PubMed Web of Science ®Google Scholar
• Kellici T, Ntountaniotis D, Vrontaki E, et al. Rational drug design paradigms: the Odyssey for designing better drugs. Comb Chem High Throughput Screen 2015;18:238–56
   PubMed Web of Science ®Google Scholar
• Doyle PS, Chen C-K, Johnston JB, et al. A nonazole CYP51 inhibitor cures Chagas’ disease in a mouse model of acute infection. Antimicrob Agents Chemother 2010;54:2480–8
   PubMed Web of Science ®Google Scholar
• De Almeida Nogueira NP, Morgado-Díaz JA, Menna-Barreto RFS, et al. Effects of a marine serine protease inhibitor on viability and morphology of Trypanosoma cruzi, the agent of Chagas disease. Acta Trop 2013;128:27–35
   PubMed Web of Science ®Google Scholar
• Engel JC, Doyle PS, Hsieh I, Mckerrow JH. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998;188:725–34
   PubMed Web of Science ®Google Scholar
• Veiga-Santos P, Barrias ES, Santos JFC, et al. Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents 2012;40:61–71
   PubMed Web of Science ®Google Scholar
• Kessler RL, Soares MJ, Probst CM, Krieger MA. Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death. PLoS One 2013;8:e55497
   PubMed Web of Science ®Google Scholar
• Soeiro MNC, Werbovetz K, Boykin DW, et al. Novel amidines and analogues as promising agents against intracellular parasites: a systematic review. Parasitology 2013;140:1–23
   PubMed Web of Science ®Google Scholar
• Santa-Rita RM, Barbosa HS, de Castro SL. Ultrastructural analysis of edelfosine-treated trypomastigotes and amastigotes of Trypanosoma cruzi. Parasitol Res 2006;100:187–90
   PubMed Web of Science ®Google Scholar
• Menna-Barreto RFS, Goncalves RLS, Costa EM, et al. The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction. Free Radic Biol Med 2009;47:644–53
   PubMed Web of Science ®Google Scholar
• Batista DGJ, Pacheco MGO, Kumar A, et al. Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi. Parasitology 2010;137:251–9
   PubMed Web of Science ®Google Scholar
• Sajid M, Robertson SA, Brinen LS, McKerrow JH. Cruzain: the path from target validation to the clinic. Adv Exp Med Biol 2011;712:100–15
   PubMed Web of Science ®Google Scholar